Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2016

01-11-2016 | Original Article

Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis

Authors: L. Susan Taichman, Catherine H. Van Poznak, Marita R. Inglehart

Published in: Supportive Care in Cancer | Issue 11/2016

Login to get access

Abstract

Introduction

Aromatase inhibitors (AIs) are a well-established component of adjuvant therapy in postmenopausal women with hormone receptor (HR) + early stage breast cancer (BCa). We explored in an 18-month cohort study whether subjective oral health (OH), subjective periodontal health (PH), and oral health-related quality of life (OHRQoL) of postmenopausal BCa survivors on AIs differ from those of women without cancer diagnoses, and whether saliva flow, OH, PH, and OHRQoL are related.

Methods

Data were collected from 29 postmenopausal BCa survivors on AIs and 29 postmenopausal women without cancer diagnoses. Socio-demographic information, OH, PH, and OHRQoL were collected at baseline and 6, 12, and 18 months later. Unstimulated whole saliva volume per 15 min was determined by drooling.

Results

The two groups did not differ in background characteristics at baseline. Women on AIs had poorer OH (p = .043), PH (p = .04), and OHRQoL (p = .017), and lower saliva flow rate (p < .001) than control respondents. BCa survivors had the poorest PH at the 18-month visit. Xerostomia was correlated with OH at baseline and with OH and PH at 18 months. However, objective saliva flow rate was not correlated with OH or OHRQoL at this visit.

Conclusions

This study is the first to investigate the effects of AIs on patients’ subjective OH, subjective PH, and OHRQoL. The data suggest that women treated with AIs have worse OH, PH, and OHRQoL than women without cancer diagnoses. Interprofessional care is recommended so that women on AIs receive optimal supportive oral care to assure long-term OH and positive OHRQoL.

Trial registration

ClinicalTrials.gov NCT01272570
https://​clinicaltrials.​gov/​ct2/​show/​NCT01272570.
Literature
1.
Gift HC, Atchison KA (1995) Oral health, health, and health-related quality of life. Med Care 33:57–77CrossRef
2.
Borgnakke WS, Ylostalo PV, Taylor GW, Genco RJ (2013) Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence. J Clin Periodontol 40:S135–S152CrossRefPubMed
3.
Brennan DS, Teusner DN (2015) Oral health impacts on self-rated general and oral health in a cross-sectional study of working age adults. Community Dent Oral Epidemiol 43:282–288CrossRefPubMed
4.
Epstein JB, Murphy BA (2010) Late effects of cancer and cancer therapy on oral health and quality of life. J Mass Dent Soc 59:22–27PubMed
5.
Ohrn K (2002) The role of oral sequelae in health-related quality of life of cancer patients. Support Care Cancer 10:656–658CrossRefPubMed
6.
Al-Ansari S, Zecha JA, Barasch A, de Lange J, Rozema FR, Raber-Durlacher JE (2015) Oral mucositis induced by anticancer therapies. Curr Oral Health Rep 2:202–211CrossRefPubMedPubMedCentral
7.
Sonis ST, Fey EG (2002) Oral complications of cancer therapy. Oncology (Williston Park) 16:680–686 discussion 86, 91-2, 95
8.
Mosel DD, Bauer RL, Lynch DP, Hwang ST (2011) Oral complications in the treatment of cancer patients. Oral Dis 17:550–559CrossRefPubMed
9.
Almazrooa SA, Woo SB (2009) Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 140:864–875CrossRefPubMed
10.
Hong CH, Napenas JJ, Hodgson BD, Stokman MA, Mathers-Stauffer V, Elting LS, Spijkervet FK, Brennan MT, Dental Disease Section, Oral Care Study Group, Multi-national Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) (2010) A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18:1007–1021CrossRefPubMedPubMedCentral
11.
Raber-Durlacher JE, Epstein JB, Raber J, van Dissel JT, van Winkelhoff AJ, Guiot HF, van der Velden U (2002) Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer 10:466–473CrossRefPubMed
12.
13.
Haverman TM, Raber-Durlacher JE, Rademacher WM, Vokurka S, Epstein JB, Huisman C, Hazenberg MD, de Soet JJ, de Lange J, Rozema FR (2014) Oral complications in hematopoietic stem cell recipients: the role of inflammation. Mediat Inflamm 2014:378281CrossRef
14.
Vozza I, Caldarazzo V, Polimeni A, Ottolenghi L (2015) Periodontal disease and cancer patients undergoing chemotherapy. Int Dent 65:45–48CrossRef
15.
Bueno AC, Ferreira RC, Barbosa FI, Ham BC, Magalhaes CS, Moreira AN (2013) Periodontal care in patients undergoing radiotherapy for head and neck cancer. Support Care Cancer 21:969–975CrossRefPubMed
16.
Fernandes LL, Torres SR, Garnica M, de Souza Gonçalves L, Junior AS, de Vasconcellos ÁC, Cavalcanti W, Maiolino A, de Barros Torres MC (2014) Oral status of patients submitted to autologous hematopoietic stem cell transplantation. Support Care Cancer 22:15–21CrossRefPubMed
17.
18.
Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MF, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796CrossRefPubMed
19.
Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051–1057CrossRefPubMed
20.
Montazeri A, Gillis CR, McEwen J (1996) Measuring quality of life in oncology: is it worthwhile? I. Meaning, purposes and controversies. Eur J Cancer Care 5:159–167CrossRef
21.
Olufade T, Gallicchio L, MacDonald R, Helzlsouer KJ (2015) Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors. Support Care Cancer 23:447–455CrossRefPubMed
22.
Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E (2012) A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms. Breast Cancer Res Treat 131:277–285CrossRefPubMed
23.
Fallowfield L, Cella D, Cuzick J, et al. (2004) Quality of life of postmenopausal women in the Arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22:4261–4471CrossRefPubMed
24.
Inglehart MR, Bagramian RA (2002) Oral health related quality of life. Quintessence Publishing, Inc, Chicago
25.
Rathbone EJ, Brown JE, Marshall HC, et al. (2013) Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol 31:2685–2691CrossRefPubMed
26.
Taichman LS, Inglehart MR, Giannobile WV, Kolenic G, van Poznak C (2015) Periodontal health in women with early-stage postmenopausal breast cancer newly on aromatase inhibitors: a pilot study. J Periodontol 86:906–916CrossRefPubMedPubMedCentral
27.
28.
Lee IC, Shieh TY, Yang YH, Tsai CC, Wang KH (2007) Individuals' perception of oral health and its impact on the health-related quality of life. J Oral Rehabil 34:79–87CrossRefPubMed
29.
Marino R, Schofield M, Wright C, Calache H, Minichiello V (2008) Self-reported and clinically determined oral health status predictors for quality of life in dentate older migrant adults. Community Dent Oral Epidemiol 36:85–94PubMed
30.
Locker D (2004) Oral health and quality of life. Oral Health Prev Dent 2(Suppl 1):247–253PubMed
31.
Sheiham A, Steele JG, Marcenes W, Finch S, Walls AW (1999) The impact of oral health on stated ability to eat certain foods; findings from the National Diet and Nutrition Survey of older people in Great Britain. Gerodontology 16:11–20CrossRefPubMed
32.
Enoki K, Matsuda KI, Ikebe K, Murai S, Yoshida M, Maeda Y, Thomson WM (2014) Influence of xerostomia on oral health-related quality of life in the elderly: a 5-year longitudinal study. Oral Surg Oral Med Oral Pathol Oral Radiol 117:716–721CrossRefPubMed
33.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457CrossRef
34.
Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Beck DJ, Taylor GW, Borgnakke WS, Page RC, Genco RJ (2013) Self-reported measures for surveillance of periodontitis. J Dent Res 92:1041–1047CrossRefPubMed
35.
Slade GD, Spencer AJ (1994) Development and evaluation of the Oral Health Impact Profile. Community Dent Health 11:3–11PubMed
36.
Mandel ID, Wotman S (1976) The salivary secretions in health and disease. Oral Sci Rev 8:25–47PubMed
37.
Ramseier CA, Kinney JS, Herr AE, Braun T, Sugai JV, Shelburne CA, Rayburn LA, Tran HM, Singh AK, Giannobile WV (2009) Identification of pathogen and host-response markers correlated with periodontal disease. J Periodontol 80:436–446CrossRefPubMed
38.
Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26:1965–1971CrossRefPubMed
39.
Streckfus CF, Baur U, Brown LJ, et al. (1998) Effects of estrogen status and aging on salivary flow rates in healthy Caucasian women. Gerontology 44:32–39CrossRefPubMed
40.
Jensen SB, Mouridsen HT, Reibel J, Brünner N, Nauntofte B (2008) Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol 44:162–173
41.
LaMonte MJ, Hovey KM, Millen AE, Genco RJ, Wactawski-Wende J (2014) Accuracy of self-reported periodontal disease in the Women's Health Initiative observational study. J Periodontol 85:1006–1018CrossRefPubMed
42.
Taichman LS, Griggs JJ, Inglehart MR (2015) Periodontal health, perceived oral health, and dental care utilization of breast cancer survivors. J Public Health Dent 75:148–156CrossRefPubMedPubMedCentral
43.
Dawes C, Pedersen AM, Villa A, et al. (2015) The functions of human saliva: a review sponsored by the World Workshop on Oral Medicine VI. Arch Oral Biol 60:863–874CrossRefPubMed
44.
Locker D (2003) Dental status, xerostomia and the oral health-related quality of life of an elderly institutionalized population. Spec Care Dentist 23:86–93CrossRefPubMed
45.
Rhodus NL, Brown J (1990) The association of xerostomia and inadequate intake in older adults. J Am Diet Assoc 90:1688–1692PubMed
Metadata
Title
Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis
Authors
L. Susan Taichman
Catherine H. Van Poznak
Marita R. Inglehart
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3336-6

Other articles of this Issue 11/2016

Supportive Care in Cancer 11/2016 Go to the issue

Original Article

Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT)

Original Article

Post-intensive care unit syndrome in gynecologic oncology patients

Original Article

Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens

Original Article

Seeing the good in the bad: which factors are associated with posttraumatic growth in long-term survivors of adolescent cancer?

Original Article

Outcome prognostic factors in inoperable malignant bowel obstruction

Original Article

Predisposing factors for postoperative nausea and vomiting in gynecologic tumor patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits